Repantis D
Department of Psychiatry and Neurosciences, Charité - Universitätsmedizin Berlin, Humboldt Universität zu Berlin, Campus Charité Mitte, Berlin, Germany.
ArticlePsychedelics
Attitudes and perceptions of psychedelic therapy among clinical trial participants with alcohol use disorder: a mixed-method study.
ArticlePsilocybin
Expectations and Motivations for Participation in Clinical Trials Utilizing Psychedelics for Treatment-Resistant Depression: A Qualitative Study.
ArticlePsychedelics
Post-traumatic stress disorder symptoms following psychedelic use: a naturalistic survey study.
ArticlePsilocybin
The role of therapeutic alliance in psilocybin treatment for treatment-resistant depression: A post hoc path analysis.
ArticleKetamine
Feeling safe: an empirical-ethical analysis of vulnerability in (es)ketamine treatment
ArticlePsychedelics
Ethical Aspects of Psychedelic-Assisted Treatments: An Overview.
ArticlePsilocybin
Corrigendum to "The role of the psychedelic experience in psilocybin treatment for treatment-resistant depression" [Journal of Affective Disorders, Volume 372 (2025), Pages 523-532].
ArticlePsychedelics
Psychedelic-assisted therapy as a complex intervention: implications for clinical trial design.
ArticlePsilocybin
Ethical issues with psychedelic-assisted treatments in psychiatry: A systematic scoping review.
ArticlePsychedelics
Offering Psychedelic Treatments Before Assisted Dying for Psychiatric Conditions.
ArticlePsilocybin
The role of the psychedelic experience in psilocybin treatment for treatment-resistant depression.
ArticlePsychedelics
Control side effects of the psychedelic renaissance.
ArticleMDMA
Study protocol for "MDMA-assisted therapy as a treatment for major depressive disorder: A proof of principle study".
ArticlePsychedelics